^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
PF-07265028
i
Other names: PF-07265028
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Pfizer
Drug class:
HPK1 inhibitor
Related drugs:
8ms
PF-07265028 As Single Agent And In Combination With Sasanlimab in Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
P1, N=18, Terminated, Pfizer | Trial completion date: Jan 2028 --> Oct 2023 | Active, not recruiting --> Terminated | Trial primary completion date: Jul 2026 --> Oct 2023; Study terminated based on internal business considerations and was not based on safety reasons
Trial completion date • Trial termination • Trial primary completion date • Combination therapy • Metastases
|
sasanlimab (PF-06801591) • PF-07265028
1year
PF-07265028 As Single Agent And In Combination With Sasanlimab in Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
P1, N=17, Active, not recruiting, Pfizer | Recruiting --> Active, not recruiting | N=240 --> 17
Enrollment closed • Enrollment change • Combination therapy • Metastases
|
sasanlimab (PF-06801591) • PF-07265028
over1year
PF-07265028 As Single Agent And In Combination With Sasanlimab in Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
P1, N=240, Recruiting, Pfizer | Trial completion date: Jul 2027 --> Dec 2027 | Trial primary completion date: Jan 2026 --> Jun 2026
Trial completion date • Trial primary completion date • Combination therapy • Metastases
|
PD-L1 expression
|
sasanlimab (PF-06801591) • PF-07265028
Share via
